Nkarta Reports Third Quarter 2026 Financial Results

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update • Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 • Cash balance of $216.0 mi

Event · Earnings
Original reporting
Published Nov 5, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NKTX
Neutral
high confidence
Mentioned
$NKTX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NKTXNeutralMed
01

Why it matters

The Q3 earnings and upcoming data release provide a catalyst for short‑term price movement; investors will price in trial risk.

02

Market read

Earnings and trial data update are the primary drivers for NKTX's near‑term market activity.

03

What to watch

Potential partnership or licensing deals not disclosed could materially improve outlook.

Relevance 7/10Novelty 8/10Timing: upcoming conference presentations Nov 8‑11
AlphAI · Earnings readNKTX · Third Quarter 2026 · ended September 30, 2026

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

Nkarta reported continued NKX019 clinical-program execution and cash expected to fund its operating plan into 2029, while third-quarter R&D expense, total operating expense and net loss were higher than the prior-year quarter.

EPS · GAAP
$ (0.45 )

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense, three months ended September 30, 2026GAAP$29.46M––
Non-cash stock-based compensation included in R&D expense, third quarter of 2026GAAP$700K––
General and administrative expense, three months ended September 30, 2026GAAP$6.31M––
Non-cash stock-based compensation included in G&A expense, third quarter of 2026GAAP$1.1M––
Total operating expenses, three months ended September 30, 2026GAAP$35.78M––
Loss from operations, three months ended September 30, 2026GAAP−$35.78M––
Interest income, three months ended September 30, 2026GAAP$2.25M––
Other income, net, three months ended September 30, 2026GAAP$206K––
Total other income, net, three months ended September 30, 2026GAAP$2.45M––
Net loss, three months ended September 30, 2026GAAP−$33.33M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.45 )––
Weighted average shares used to compute net loss per share, basic and diluted, three months ended September 30, 2026GAAP74,637,689––
Research and development expense, nine months ended September 30, 2026GAAP$83.50M––
General and administrative expense, nine months ended September 30, 2026GAAP$26.28M––
Total operating expenses, nine months ended September 30, 2026GAAP$109.8M––
Loss from operations, nine months ended September 30, 2026GAAP−$109.8M––
Interest income, nine months ended September 30, 2026GAAP$7.62M––
Other income, net, nine months ended September 30, 2026GAAP$634K––
Total other income, net, nine months ended September 30, 2026GAAP$8.26M––
Net loss, nine months ended September 30, 2026GAAP−$101.5M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (1.36 )––
Weighted average shares used to compute net loss per share, basic and diluted, nine months ended September 30, 2026GAAP74,464,897––
Non-cash charges included in net loss, third quarter of 2026GAAP$2.8M––
Cash, cash equivalents, restricted cash and investments, September 30, 2026GAAP$216.0M––
Property and equipment, net, September 30, 2026GAAP$54.59M––
Operating lease right-of-use assets, September 30, 2026GAAP$30.5M––
Other assets, September 30, 2026GAAP$7.34M––
Total assets, September 30, 2026GAAP$308.5M––
Accounts payable, accrued and other liabilities, September 30, 2026GAAP$20.68M––
Operating lease liabilities, September 30, 2026GAAP$72.04M––
Total liabilities, September 30, 2026GAAP$92.71M––
Stockholders' equity, September 30, 2026GAAP$215.7M––
Total liabilities and stockholders' equity, September 30, 2026GAAP$308.5M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Current operating plan outlook

  • NoteNkarta expects its current cash and cash equivalents to fund its current operating plan into 2029.

What drove it

  • Initial clinical data from the Ntrust program in idiopathic inflammatory myopathy and systemic sclerosis are scheduled for presentation at ACR Convergence 2026.
  • Enrollment continues in the multi-center, open-label, dose-escalation Ntrust program.
  • Outpatient dosing is underway within a network of community-based sites.
  • Patients are being dosed at 4 billion cells per dose x 3 doses (12 billion cells total) across all indications in Ntrust-1 and Ntrust-2.

Concerns

  • Net loss was $ (33,326 ) (in thousands) for the three months ended September 30, 2026, versus $ (21,715 ) (in thousands) for the prior-year period.
  • R&D expense was $ 29,464 (in thousands) for the three months ended September 30, 2026, versus $ 20,198 (in thousands) for the prior-year period.
  • The company stated that initial, interim or preliminary clinical data may reflect a limited number of patients with limited follow-up and may change as additional data become available.
  • Nkarta has no products approved for sale, according to the forward-looking-statement risk discussion.

What to watch

  • The oral presentation in myositis on November 8 at ACR Convergence 2026.
  • The systemic sclerosis poster on November 9 at ACR Convergence 2026.
  • The oral presentation of safety data across autoimmune indications on November 11 at ACR Convergence 2026.
  • Continued enrollment and outpatient dosing in Ntrust-1 and Ntrust-2.
  • Execution against the stated expectation that current cash and cash equivalents will fund the current operating plan into 2029.

Balance sheet and cash flow

  • Cash, cash equivalents, restricted cash and investments were $216.0 million as of September 30, 2026.
  • Cash, cash equivalents, restricted cash and investments: $ 216,026 (in thousands) at September 30, 2026; $ 295,129 (in thousands) at December 31, 2025.
  • Total assets: $ 308,461 (in thousands) at September 30, 2026; $ 404,209 (in thousands) at December 31, 2025.
  • Total liabilities: $ 92,712 (in thousands) at September 30, 2026; $ 91,884 (in thousands) at December 31, 2025.
  • Operating lease liabilities: $ 72,037 (in thousands) at September 30, 2026; $ 76,420 (in thousands) at December 31, 2025.
  • Stockholders' equity: $ 215,749 (in thousands) at September 30, 2026; $ 312,325 (in thousands) at December 31, 2025.

Analysis

Nkarta's third-quarter update was centered on clinical execution for NKX019 rather than commercial activity. The company said enrollment continues in Ntrust-1 and Ntrust-2, with outpatient dosing underway at community-based sites. Patients are being dosed at 4 billion cells per dose x 3 doses (12 billion cells total) across all indications in the two trials. The filing did not report revenue or operating segments.

The near-term clinical catalyst is ACR Convergence 2026. Nkarta plans an oral myositis presentation on November 8, a systemic sclerosis poster on November 9, and an oral safety presentation across autoimmune indications on November 11. These presentations concern initial clinical data from the Ntrust program in the company's lead indications of idiopathic inflammatory myopathy and systemic sclerosis.

Operating spending increased versus the prior-year quarter. R&D expense was $ 29,464 (in thousands), compared with $ 20,198 (in thousands), and total operating expenses were $ 35,777 (in thousands), compared with $ 27,286 (in thousands). G&A expense was $ 6,313 (in thousands), compared with $ 7,088 (in thousands). Net loss was $ (33,326 ) (in thousands), or $ (0.45 ), compared with $ (21,715 ) (in thousands), or $ (0.29 ). Interest income was $ 2,245 (in thousands), below $ 3,852 (in thousands) in the prior-year quarter.

Liquidity remains the principal financial support for the development plan. Cash, cash equivalents, restricted cash and investments were $ 216,026 (in thousands) at September 30, 2026, compared with $ 295,129 (in thousands) at December 31, 2025. Nkarta expects its current cash and cash equivalents to fund its current operating plan into 2029. No operating cash flow, free cash flow, share repurchases, dividends, revenue guidance, expense guidance, or tax-rate guidance was reported.

Management, verbatim

NKX019 is advancing in our two lead indications, myositis and systemic sclerosis.

Paul J. Hastings, Chief Executive Officer of Nkarta

We’re delighted to have been selected to present our initial clinical data in two oral presentations and one poster presentation at ACR Convergence 2026 in Orlando.

Paul J. Hastings, Chief Executive Officer of Nkarta

We believe that the safety profile of engineered CAR-NK cells could broaden cell therapy access to reach far more patients.

Paul J. Hastings, Chief Executive Officer of Nkarta

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons were not reported.
  • Gross profit and gross margin were not reported.
  • Operating cash flow, free cash flow and a cash-flow statement were not reported.
  • Non-GAAP financial metrics were not reported.
  • Segment revenue and segment profitability were not reported.
  • Share repurchases, dividends and other capital-return activity were not reported.
  • Prior-quarter comparisons were not reported for the financial-statement line items.
  • Revenue, gross-margin, operating-expense and tax-rate numerical guidance were not reported.
  • A prior outlook section was not provided, so no comparison with prior guidance is available.
  • Debt other than operating lease liabilities was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Nkarta is a clinical‑stage biotech developing engineered NK cell therapies for autoimmune diseases.

Company-level read

Ticker impact

$NKTXNeutralHigh confidence
Context

Nkarta reported Q3 2026 cash of $216M, net loss $33.3M and announced upcoming clinical data presentations for NKX019 at ACR Convergence 2026.

Expected impact

likely modest pressure as investors await clinical data, with upside potential if results exceed expectations

Evidence & confidence

Cash balance supports operations to 2029, but lack of product revenue and ongoing losses keep the stock risk‑on pending data.

Market effects

Highlights continued investment in off‑the‑shelf CAR‑NK therapies, may influence biotech sector sentiment.

Primarily U.S. biotech investors; limited broader regional effect.

Clinical data could attract global biotech interest but impact remains niche.

Counterpoint

Despite cash runway, the high burn rate and lack of revenue suggest a bearish stance until data de‑risk.

Key entities

  • Nkarta, Inc.

    Clinical‑stage biotech developing NK cell therapies.

  • NKX019

    Allogeneic CAR‑NK cell candidate targeting CD19 for autoimmune indications.

Every NKTX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NKTXHighAI 8/10

Nkarta reports safety data for autoimmune cell therapy NKX019

Nkarta Inc. (NKTX) presented safety data for NKX019, its CD19-directed CAR NK cell therapy, in a clinical trial for autoimmune diseases. The data, from 40 patients, showed no serious adverse events. Treatment-emergent adverse events occurred in 85% of patients, with 35% experiencing grade 3 or higher events, primarily hematologic. NKX019 is manufactured from donor-derived NK cells.

$NKTXMedAI 8/10

Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials

Nkarta (NKTX) presented early clinical data for NKX019, showing positive responses in myositis and systemic sclerosis trials. 83% of myositis patients and 86% of systemic sclerosis patients responded to treatment. Safety data from 40 patients showed no serious adverse events. Nkarta plans to evaluate a higher dose and engage with the FDA for potential registration pathways.

$NKTXMedAI 9/10

Nkarta reports early trial data for autoimmune cell therapy

Nkarta Inc. (NKTX) presented early trial data for NKX019, an experimental cell therapy for autoimmune diseases. In trials with 40 patients, 83% of myositis patients and 86% of systemic sclerosis patients showed significant responses. No serious adverse events were reported. Nkarta plans to evaluate higher doses and discuss potential registration pathways with the FDA.

$NKTXLow

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer